LY3009120

NRAS proto-oncogene, GTPase ; Homo sapiens







3 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34539849 Pan-RAF inhibitor LY3009120 is highly synergistic with low-dose cytarabine, but not azacitidine, in acute myeloid leukemia with RAS mutations. 2021 Nov 1
2 29059158 RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. 2018 Feb 8 1
3 26343583 Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. 2015 Sep 14 1